November 19, 2008

ورود Durezol به بازارهای جهانی

Posted by Admin at 03:33 PM | Comments (0)

قطره چشمی Bepreve برای کنترل خارش چشم

Posted by Admin at 03:28 PM | Comments (0)

November 18, 2008

Retina Regeneration Therapy effective in ME

AAO 2008
Ellex 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR). Ellex 2RT uses a green YAG laser to target the retinal pigment epithelium with 532 nm light energy, delivered in three-nanosecond pulses. Researchers treated the newly-diagnosed diabetic maculopathy of 23 patients (eyes, n=38) with Ellex 2RT to modify the macular grid pattern. Of the patients enrolled in the trial, 17 eyes (n=28) completed the six-month follow-up period. At the six-month follow-up visit, central macular thickness had decreased by ≥5% from baseline in 46% of patients; it remained stable in 39% of patients and increased by ≥5% in the remaining 15%. Hard exudates were decreased in >50% of treated eyes. An improvement of ≥2 lines of LogMar visual acuity was observed in 43% of eyes; of 1–2 lines, in 28%. Visual acuity remained stable in 15% of eyes and decreased in 14%. The device's manufacturers, Ellex, now plans to investigate the role of Ellex 2RT as a therapeutic in other indications, including age-related macular degeneration and central serous retinopathy.

Posted by Kamran Jalali, MD at 08:32 PM | Comments (0)

November 17, 2008

لیزر تراپی، درمان اصلی رتینوپاتی دیابتی

Posted by Admin at 12:32 PM | Comments (0)

بهبود BCVA در تنبلی چشم یک طرفه با استفاده از برنامه NeuroVision

Posted by Admin at 12:28 PM | Comments (0)

ضعف MRI در تشخیص تهاجم به عصب بینائی در رتینوبلاستوما

Posted by Admin at 12:25 PM | Comments (0)

درمان ادم ماکولای دیابتی با استفاده از پلاسمین

Posted by Admin at 12:12 PM | Comments (0)

November 12, 2008

نیاز به درمان های جدید برای خشکی چشم متوسط و شدید

Posted by Admin at 05:50 PM | Comments (0)

ارتباط عطسه دربی حسی موضعی با نوع دارو و عمق sedation

Posted by Admin at 05:10 PM | Comments (0)

موثرتر بودن داروهای anti-VEGF در درمان DME از لیزرتراپی و .......

Posted by Admin at 05:05 PM | Comments (0)

November 11, 2008

Pars plana approach preferred for anterior vitrectomy

AAO 2008
If the posterior capsule breaks during cataract surgery and vitreous presents to the anterior chamber, patients are best served by anterior vitrectomy using a pars plana technique. When handled properly, the potential outcome after posterior capsule rupture can rival that of an uncomplicated case both anatomically and visually, but only if surgeons adhere to several fundamental surgical principles. These principles are best achieved using a pars plana approach to vitrectomy. One of the advantages of the pars plana vitrectomy approach is that it enables a truly closed chamber environment, which also reduces intraocular turbulence, because the phaco incision is hydrated, sutured, and sealed. Importantly, the pars plana approach also allows a more limited yet more thorough clean-up of vitreous in a safer fashion relative to performing vitrectomy through the limbus. Because the vitreous is being pulled down, the pars plana technique allows definition of a better endpoint and can potentially decrease vitreoretinal tractional forces. As another benefit, the pars plana approach affords better access to remaining lens material, especially within the subincisonal area that can be difficult to reach from the limbus. In addition, the pars plana technique is more likely to preserve capsular support for IOL placement.

Posted by Kamran Jalali, MD at 08:51 PM | Comments (0)

Distinct patterns of diabetic maculopathy seen on OCT

AAO 2008
Optical coherence tomography (OCT) is valuable in managing diabetic macular edema (DME), more so than fluorescein angiography, in which the degree of leakage is not correlated with visual acuity and outcomes. In addition, angiography does not show vitreoretinal abnormalities that may require a different treatment. OCT provides a retinal thickness map that correlates well with leakage clinically, fluorescein leakage, and more importantly, with decreased visual acuity. The maps can be used to track progression and treatment efficacy. The OCT single scan tomograms identify specific patterns in patients with DME. The patterns may have different prognoses and require different management. It is important to recognize the patterns on OCT. The sponge-like pattern is the one most commonly seen in which the inner layers of the retina appear to be compressed as the result of fluid absorption. This pattern responds well to laser treatment. Cystoid macular edema is characterized by cysts that grow and coalesce and are associated with worse visual acuity than with the sponge-like pattern; this responds to steroids and anti-vascular endothelial growth factor drugs. Serous retinal detachment without posterior hyaloidal traction is characterized by serous fluid in the fovea not seen on ophthalmoscopy; treatment and absorption of the fluid often leads to the hard exudates deposits in the subretinal space. Posterior hyaloidal traction leading to DME seems to be a distinct subgroup of patients. The traction is subtle but can be identified by sheen on clinical examination. Traction can cause a traction retinal detachment in a few patients. If there is traction that is more tangential resulting from the hyaloidal traction, it can be very subtle. A retinal detachment can occur without traction; this does not respond to laser or medical therapy but requires vitrectomy. There are six morphologic patterns on OCT of DME that may represent distinct entities that require different treatment regimens. Identifying the patterns allows more effective management of these patients.

Posted by Kamran Jalali, MD at 08:43 PM | Comments (0)

November 10, 2008

عوارض چشمی در بیماران گلوکومی تحت درمان

Posted by Admin at 03:48 PM | Comments (0)

استفاده از تجریبات روماتولوگ ها در درمان یووئیت بدون استفاده از کورتون

Posted by Admin at 03:23 PM | Comments (0)

میزان بالای جراحی های عیوب انکساری در چشم پزشکان و خانواده آنها

Posted by Admin at 03:08 PM | Comments (0)

November 09, 2008

Next-generation calcineurin inhibitor in pivotal trials for noninfectious uveitis

AAO 2008
Enrollment has been completed in a series of phase III studies investigating voclosporin (Lumeniq, Lux Biosciences) as a steroid-sparing agent for the treatment of noninfectious uveitis. Voclosporin, formerly known as LX211, is a next-generation calcineurin inhibitor that, based on its evaluation in other indications, appears to have a better safety profile compared with other calcineurin inhibitors, including cyclosporine A and tacrolimus. In addition, results from evaluation of voclosporin in experimental models of autoimmune uveitis showed its use was associated with preservation of retinal structure and function.

Posted by Kamran Jalali, MD at 09:08 PM | Comments (0)

Ciliary neurotrophic factor may be therapeutic for RP

AAO 2008
Ciliary neurotrophic factor (CNTF), a member of the interleukin family of proteins, seems to be safe and promising for treating patients with retinitis pigmentosa (RP) when delivered into the eye via sequestered live cell intraocular implants. In a phase I non-randomized, open-label clinical trial, CNTF, which has been shown in animal models to rescue photoreceptors from death, was introduced in one eye of 10 patients through a small incision in the sclera in a 6- × 1-mm implant. CNTF is then released into the vitreous. Five patients received low-dose implants and five received higher-dose implants. The capsules remained implanted for 6 months before they were explanted. Preoperatively, three patients had little visual acuity, and seven eyes had measurable visual acuity. The outcome of the safety study was good and provided the basis for going forward with other studies; however, more specifically, there was a remarkable change in visual function exceeding 10 letters in three patients. These patients with RP with macular atrophy began to recover visual function halfway through the study. There was no change in the untreated fellow eye. The improvement in visual acuity was sustained 6 months after the implants were removed. This result led to the idea to use CNTF for geography atrophy in age-related macular degeneration. The question that must be addressed regarding these patients is how CNTF actually improves visual function. CNTF may be able to rescue dormant-but-not-dead photoreceptors. It is possible that the photoreceptors may remain viable even though they are not functioning.

Posted by Kamran Jalali, MD at 09:01 PM | Comments (0)